Busschots, Dana http://orcid.org/0000-0003-0887-4119
Kremer, Cécile
Bielen, Rob
Koc, Özgür Muhammet
Heyens, Leen
Dercon, Eefje
Verrando, Rita
Windelinckx, Tessa
Maertens, Griet
Bourgeois, Stefan
Hens, Niel
Matheï, Catharina
Robaeys, Geert
Clinical trials referenced in this document:
Documents that mention this clinical trial
Identification and treatment of viral hepatitis C in persons who use drugs: a prospective, multicenter outreach study in Flanders, Belgium
https://doi.org/10.1186/s12954-021-00502-7
Funding for this research was provided by:
Gilead Sciences (V-2330)
AbbVie (V-2656)
Article History
Received: 30 November 2020
Accepted: 9 May 2021
First Online: 17 May 2021
Declarations
:
: The study was approved by the Ethical Committee of Ziekenhuis Oost-Limburg and Hasselt University (18/0052U). The study protocol is registered at clinicaltrials.gov (NCT04363411). The study was conducted in accordance with the provisions of the Declaration of Helsinki and its amendments. Good clinical practice guidelines were followed throughout the study and all participants provided written informed consent.
: Not applicable.
: D.B. has received travel grants from AbbVie and Gilead Sciences and research grants from Gilead; R.B. has received travel grants from AbbVie, Gilead Sciences, and MSD and research grants from Gilead and MSD; Ö.K. has received a travel grant and research grants from Gilead and CyTuVax BV; N.H. has received grants from GlaxoSmithKline (GSK), grants from Johnson & Johnson pharmaceuticals and grants from Pfizer; C.M has received travel grants from Gilead, MSD Belgium, and INDIVIOR and has acted as consultant for MSD Belgium; G.R. has received research grants from AbbVie, Janssen Pharmaceuticals, MSD, and has acted as a consultant/advisor for AbbVie, BMS, Gilead Sciences, and MSD. All other co-authors report no competing interests.